Instructor in Medicine, Dana-Farber Cancer Institute
Hematology
Dr. James E. Butrynski, MD
|
|
Give Review
James Butrynski practices Hematology. He graduated from Wayne State University School of Medicine. Wayne State University School of Medicine is ranked 63 in research and 85 in primary care medicine He received awards:"Regional Top Doctor". James E. Butrynski is a published doctor and has 30 publications published. The lastest was: 'Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.' James Butrynski accepts Medicare.
Publications
- Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
- An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center.
- Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors.
- Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy.
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial.
- Esophageal gastrointestinal stromal tumor: report of 7 patients.
- A to z of desmoid tumors.
- PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
- A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma.
- Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
- Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
- Primary extragastrointestinal stromal tumor of the pleura: report of a unique case with genetic confirmation.
- Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.
- [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
- Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
- Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas.
- Small molecule tyrosine kinase inhibitor and depression.
- [18F]Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors.
- Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates.
- Differential isoprenylation of carboxy-terminal mutants of an inhibitory G-protein alpha-subunit: neither farnesylation nor geranylgeranylation is sufficient for membr...
- G-protein beta gamma dimers. Membrane targeting requires subunit coexpression and intact gamma C-A-A-X domain.
- The G protein connection: molecular basis of membrane association.
- Management of adult soft-tissue sarcoma of the extremities and trunk.
- Type of post-grafting immunosuppression after non-myeloablative blood cell transplantation may influence risk of delayed haemolysis due to minor ABO incompatibility.
- Imaging of radiation-associated sarcoma.
- Clinical presentation and management of mTOR inhibitor-associated stomatitis.
- Extraskeletal osteosarcoma: spectrum of imaging findings.
- The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
- Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Schools
Wayne State University School Of Medicine
Massachusetts General Hospital
NIH
University Of Washignton Seattle Wa
Procedures Preformed
- Biological Therapy
- Bone Marrow Aspiration
- Breast Cancer Treatment
- Cancer Counseling
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Washington -
National Institutes of Health Clinical Center -
Massachusetts General Hospital -
Wayne State University School of Medicine
Hospital
-
Dana-Farber Cancer Institute -
Brigham and Women's Hospital -
Massachusetts General Hospital -
Overlake Medical Center
Drug Facts
| NPI NUMBER | 1427134287 | |
| NPPES Provider LastName | BUTRYNSKI | |
| NPPES Provider FirstName | JAMES | |
| NPPES Provider ZIPCode | 021156013 | |
| NPPES Provider State | MA | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 233.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1427134287 |
| Last Name Of The Provider | BUTRYNSKI |
| First Name Of The Provider | JAMES |
| View All |
Similar Doctors
|
Dr. Jason C. Comer, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Richard S. Chang, MD |
|
|
Dr. Otero V. Flowers, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kenneth Kraemer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn D. Crossland, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas L. Kovach, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John W. Smith, MD |
|
Dr. Goldy Bansal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Winnifred B. Oldham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin Song, MD |
|
|
Dr. Joshua D. Field, DPT
This Doctor is OpenDoctor Recommended.
|
|
|
Dan Wu, LAC |